83 results
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
7 May 24
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
4:05pm
(expense), net
Loss before income tax expense
Income tax expense
Net loss
Basic and diluted net loss per common share
Weighted-average number of shares
PRE 14A
ALGS
Aligos Therapeutics Inc
16 Apr 24
Preliminary proxy
5:27pm
.
Year Ended December 31,
(in thousands)
Audit Fees(1)
Audit-Related Fees
Tax Fees
All Other Fees
Total Fees
Audit fees consist of fees … all of the audit, audit-related, tax and other services provided by EY for 2023 and 2022, including the audit, audit-related, tax and other services
8-K
EX-99.1
kvn88h mdp14r6ix
12 Mar 24
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
4:06pm
SC TO-I
EX-99
18494 1twff
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
vl0 0v9y7z4lk69
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
eofyx7pjs ut6p
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
xm8q52e
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
i19uvj
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
qe3 tparx
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
6r486
30 Jan 24
Issuer tender offer statement
7:04am
8-K
EX-99.1
5nss3i
2 Nov 23
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
4:05pm
8-K
EX-10.1
jyk5x7e drpr
25 Oct 23
Entry into a Material Definitive Agreement
5:05pm